阿哌沙班逆转治疗双侧肾上腺出血合并活动性深静脉血栓及肝素诱导性血小板减少症:一例病例报告
本文报告一例71岁女性在阿哌沙班抗凝期间发生双侧肾上腺出血,同时存在活动性左股总静脉深静脉血栓和近期肝素诱导性血小板减少症(HIT)病史。因活动性血栓和HIT病史限制4因子凝血酶原复合物及andexanet alfa的使用,经医患共同决策后给予andexanet alfa逆转,患者血流动力学稳定并后续重启预防剂量磺达肝癸钠。
要点
- 活动性血栓合并HIT病史使阿哌沙班逆转策略选择受限,需个体化决策。
- 双侧肾上腺出血可表现为休克,需警惕肾上腺危象并给予糖皮质激素支持。
- andexanet alfa在活动性血栓患者中数据有限,需权衡出血与血栓风险。
核心结论
- 本例提示双侧肾上腺出血、活动性血栓和HIT并存时,指南导向的逆转策略有限,需个体化多学科决策。
研究设计与样本
- 单例病例报告:71岁女性,有骨科创伤史,住院期间发生HIT并转为磺达肝癸钠,后因左股总静脉深静脉血栓出院时使用阿哌沙班。
主要发现
- 出院后48小时内因休克就诊,计算机断层扫描显示双侧肾上腺出血,考虑肾上腺危象。
- 因活动性血栓和HIT病史,4因子凝血酶原复合物被排除,andexanet alfa使用受机构政策和血栓事件数据有限限制。
- 经共同决策后给予andexanet alfa,患者经糖皮质激素支持稳定,需置入下腔静脉滤器,后重启预防剂量磺达肝癸钠并转至专业护理机构。
临床怎么用
- 对接受阿哌沙班抗凝且近期有HIT和活动性血栓的患者,发生肾上腺出血时需多学科评估逆转策略。
- andexanet alfa可在危及生命的出血中考虑使用,但需充分告知血栓风险并共同决策。
- 肾上腺出血患者应给予糖皮质激素支持并监测血流动力学。
局限性
- 单例病例报告,结论外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe the management challenges of bilateral adrenal hemorrhage (BAH) in a patient on apixaban with recent heparin-induced thrombocytopenia (HIT) and active deep vein thrombosis (DVT). SUMMARY: A 71-year-old woman with a history of orthopedic trauma developed HIT during hospitalization and was transitioned to fondaparinux. She was later discharged on apixaban for treatment of a provoked left common femoral DVT. Within 48 hours, she presented with shock initially attributed to sepsis. Computed tomography revealed BAH, raising concern for adrenal crisis. Reversal of apixaban was urgently considered but complicated by the patient's active thrombosis and history of HIT, which excluded the use of 4-factor prothrombin complex concentrate and posed challenges to the use of andexanet alfa given institutional policy and the limited data in patients with thrombotic events. After shared decision-making with the patient and family, andexanet alfa was administered given the life-threatening nature of the hemorrhage. The patient stabilized with corticosteroid support, required placement of an inferior vena cava filter, and was later restarted on prophylactic-dose fondaparinux. She was discharged to a skilled nursing facility with recovery of hemodynamic stability. CONCLUSION: This case illustrates the intersection of BAH, active thrombosis, and HIT, where guideline-directed reversal strategies are limited. It underscores the challenges of selecting and timing anticoagulation reversal in patients with recent thrombotic events and contraindications to standard agents, highlighting the importance of individualized, interdisciplinary decision-making in managing complex anticoagulation scenarios.
引用
- Lichardi M, Moriarty S, Nicholas H, et al. Adrenal hemorrhage requiring apixaban reversal in the setting of active deep vein thrombosis and heparin-induced thrombocytopenia: A case report. Am J Health Syst Pharm. 2026. PMID: 41776964. doi:10.1093/ajhp/zxag059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。